68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen
(PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian
cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a
radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged
using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far
the disease has spread.